WEAVER BIOSCIENCES
Live / Allowed — Notice of allowance issued (as of 15 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 15 Sept 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99393423
- Mark type
- Stylized text
- Filed
- 15 Sept 2025
- Published for opposition
- 21 Jul 2026
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 001 — Chemicals: Biological preparations for use in industry and science and chemical agents for use in industry and science; biological preparations comprising of small molecules for use in scientific research; bacterial and viral substances other than for medical and veterinary uses; chemicals and biological chemical preparations for use in medical science, namely, for use in biochemical and clinical research
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of cancer, immune system diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, respiratory diseases and disorders, infectious diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, hematological diseases and disorders, and gastroenterological diseases and disorders
- Class 042 — Scientific and technological services: Scientific research and pharmaceutical development services; development of gene-based medicines; medical and scientific research in the fields of genetics, genomics, gene modulation and genetic engineering; DNA and RNA analysis and sequencing services for scientific and research purposes; research, development and scientific consultancy in the field of genomics and gene modulation; scientific research in the field of biology, molecular biology, cell biology, biotechnology, bacteriology, immunology, genetics, medicine, pharmacology, virology, chemistry, scientific research of vaccines, and antibiotics; providing online non-downloadable software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of disease, biomedical, and genomic research; providing online non-downloadable software using artificial intelligence, computational methods, and machine learning models for the design and characterization of therapeutic products and drug analysis in the field of drug discovery and development; providing online non-downloadable software using artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, molecular, biochemical, and biomarker information, associations, conditions, outcomes, effects and risks
Owner
- Weaver Biosciences, Inc., Boston, MA, US
- Weaver Biosciences, Inc., Boston, MA, US
Prosecution history
- 15 Sept 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 21 Jul 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Jul 2026 — PUBLISHED FOR OPPOSITION
- 15 Jul 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Jun 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Jun 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Jun 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Jun 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Mar 2026 — NON-FINAL ACTION E-MAILED
- 19 Mar 2026 — NON-FINAL ACTION WRITTEN
- 18 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 18 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 18 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 09 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED